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Abstract
Background Recurrent urethral stricture is usually treated with either open urethroplasty or endoscopic urethrotomy. Both 
of the procedures cause short-term utility loss, which may not be captured by standard utility questionnaires due to the chal-
lenges of completing a standard instrument at the time of an acute episode of short duration, especially within a clinical trial 
setting. We propose to use time trade-off (TTO) methods to estimate these short-term utility losses.
Objective The aim was to compare the use of two alternative TTO methods to elicit patients’ short-term utilities following 
surgical treatments for recurrent urethral stricture.
Method Two variants of TTO (chained and conventional) were used. Six health profiles were developed—three for each 
procedure. Forty participants took part, with 20 randomly allocated to each TTO method.
Results Thirty-eight participants provided usable data for analysis. Estimated utility values decreased as the severity of the 
health profiles increased. There was no evidence that utility values differed between elicitation methods or procedures for mild 
{ranging from 0.79 (standard deviation [SD] 0.17) to 0.83 [SD 0.20]} and moderate (ranging from 0.54 [SD 0.24] to 0.67 [SD 
0.21]) health states, although they appeared to differ for severe health states (ranging from 0.29 [SD 0.20] to 0.56 [SD 0.24]).
Conclusion The study demonstrates the feasibility and value of eliciting patients’ short-term utilities. Given the small sample size, 
the study findings are tentative. Further research with a larger sample size is needed to determine the appropriate TTO method 
to use and how the elicited utilities can be used in combination with standard cost-utility assessments to aid decision making.
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1 Introduction
There is a growing emphasis on measuring and evaluat-
ing patients’ health-related quality-of-life (HRQoL), which 
is converted into utility values used in economic evalu-
ations. As an important outcome, it is key to ensure all 
Key Points for Decision Makers 
This study makes the first attempt to compare the use of 
two alternative time trade-off methods to elicit patients’ 
short-term utilities following surgical treatments.
The study shows the feasibility and value of eliciting 
patients’ utilities as part of a clinical trial when routine 
data collection was not able to capture all utilities.
The choice of elicitation method may depend on the sever-
ity of health states to detect any meaningful difference.
utilities are captured in the analysis to ensure a robust and 
accurate comparison between treatment strategies. This 
is sometimes difficult to achieve due to a combination 
of the fixed frequency of HRQoL data collection, unpre-
dictable recurrence of disease-specific events that impact 
on patients’ HRQoL, and the unfeasibility of collecting 
HRQoL data immediately after such events. This is the 
case in the OPEN (Open Urethroplasty versus Endoscopic 
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impact is measured in terms of utility values that usually 
fall between 0 and 1, where 0 is equated to ‘being dead’ and 
1 ‘being in perfect health’, though negative values are pos-
sible for health states considered worse than death [7]. The 
TTO method has mostly been used to elicit utility values for 
chronic health states where participants typically remain in 
the impaired health state for 10 years or more [8], and we 
have termed this as a ‘conventional TTO’. However, the two 
surgical procedures in the OPEN study were likely to have a 
short-term impact on patients’ HRQoL over days or weeks 
post-operatively before the patients returned to usual health. 
In these circumstances, a conventional TTO exercise may 
become less responsive [9, 10]. This is because the exercise 
offers an unrealistic choice between an impaired health state 
for a fixed duration and a perfect health state for a shorter 
duration of time, both followed by death. Attempts to rem-
edy this problem have involved using an intermediate health 
state rather than directly comparing the temporary health 
state to perfect health and death, and this method is referred 
to as the ‘chained TTO’ [11]. However, little research has 
been done on the performance of conventional and chained 
TTO methods in eliciting short-term utility values. As an 
exploratory first attempt, the aims of this TTO study were, 
therefore:
– To assess the feasibility of eliciting short-term utilities 
for health states resulting from treatments investigated in 
a clinical trial.
– To tentatively compare utility values elicited using con-
ventional and chained TTO methods.
2  Methods
2.1  Participants
The TTO study took place in parallel with the OPEN trial. 
The TTO participants were recruited from those who were 
eligible for the OPEN trial: males aged 16 years or over, with 
a stricture located predominantly in the bulbar urethra, who 
had undergone at least one previous intervention for bulbar 
urethral stricture; clinical and patient agreement that further 
intervention was required; patients suitable for necessary 
anaesthesia who were willing to undergo up to 2 weeks of 
catheterisation and provided written consent for study par-
ticipation. All screened eligible OPEN trial patients were 
asked to indicate whether they would be interested in par-
ticipating in an interview study regardless of their decision 
about whether to participate in the main OPEN trial. Those 
who expressed interest were posted a TTO Study Informa-
tion Pack containing a response slip and pre-paid envelope. 
Upon receipt of an affirmative response slip, a researcher 
contacted respondents to answer any further questions and 
Urethrotomy) study [1], which was a randomised con-
trolled trial comparing two treatment strategies (open ure-
throplasty versus endoscopic urethrotomy) for men with 
recurrent urethral stricture. Urethral stricture is a narrow-
ing of the urethra caused by scarring after injury or infec-
tion and is the most common cause of difficulty passing 
urine in younger and middle-aged men [2]. Endoscopic 
urethrotomy, a procedure in which the stricture is divided 
using an instrument passed along the urethra, is com-
monly performed for recurrent bulbar stricture because it 
is minimally invasive, does not require specialist surgical 
expertise, and has a short period of urethral catheterisa-
tion and recovery. However, further recurrence is likely 
[3]. Open urethroplasty, where the urethra is surgically 
reconstructed through an incision in the perineum, is more 
invasive, requires specialist expertise and a longer period 
of catheterisation and may be complicated by wound pain 
and infection. It does, however, offer the prospect of long-
term cure without the need for further interventions [4, 5]. 
The current decision-making process in the UK National 
Health Service (NHS) is influenced by availability of local 
expertise, clinician guidance as well as patient preferences.
The OPEN trial aimed to compare the clinical- and cost-
effectiveness of alternative treatments for recurrent ure-
thral stricture in men and resolve uncertainty as to whether 
men with a recurrent urethral stricture are best treated by 
endoscopic urethrotomy or open urethroplasty [1]. The 
health economic component of the OPEN study measured 
the effects of the procedures in terms of quality-adjusted 
life years (QALYs) derived from the EQ-5D-5L question-
naire administrated at baseline and then at a 6-monthly 
interval. Because of the invasiveness of the procedures 
and their associated side effects, participants’ HRQoL was 
likely to temporarily deteriorate post-treatment, but this 
would not be captured by completion of a later scheduled 
EQ-5D as respondents were asked about health on the day 
the questionnaire was completed. Furthermore, the recur-
rence of urethral stricture is unpredictable.
This proves a challenge, as data collection at fixed time 
periods has the potential to miss short-term but frequent 
changes to HRQoL, and within a large-scale, multi-centre 
study, it is not feasible to collect data using an individualised 
follow-up schedule. Furthermore, it is usually not acceptable 
in terms of participant burden to ask participants to complete 
an HRQoL questionnaire at the time of the event occurrence 
when they are unwell. Therefore, a time trade-off (TTO) 
exercise was conducted to elicit the short-term utilities that 
would otherwise be missed.
TTO is one of a number of methods to measure prefer-
ences for temporary health states for cost-utility analysis [6], 
eliciting the impact of impaired health on individuals’ qual-
ity of life by asking participants to state preferences between 
quality and quantity of life in hypothetical scenarios. The 
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arrange a time and place of the participant’s choosing to 
conduct the TTO interview.
2.2  TTO Materials
Three health state profiles were created for each proce-
dure, representing ‘mild’, ‘moderate’ and ‘severe’ health 
states based on the severity of side effects following each 
procedure. The profiles were developed based on consulta-
tion with clinicians (urologists from the OPEN trial main 
site) and a patient co-investigator, as well as findings from 
qualitative interviews conducted in the pilot phase of the 
trial where participants provided a personal account of their 
symptoms and the impact on their quality of life [12]. The 
time horizon chosen for the health states was based on the 
shortest time length during which most of the side effects 
would occur—14 days. The urethrotomy profiles focused on 
differing severities of urinary symptoms: discomfort from 
the catheter, bleeding on urination, urinary tract infection 
and erectile dysfunction. While the nature of the symptoms 
was similar for each level of severity, these were differenti-
ated by descriptors (e.g. brief/serious) and the addition of 
more serious side effects such as infections. The urethro-
plasty profiles were nearly identical but incorporated the 
additional symptoms from the graft donor site in the mouth 
and perineal wound. Profiles are presented in Appendix 1 
[see the electronic supplementary material (ESM)]. The 
anchor state [9, 10] for use in the chained TTO version 
described an injured state in which basic tasks could be car-
ried out but usual activities such as work and socialising 
were not possible and pain was constant (Appendix 2; see 
the ESM). Piloting of the health states and the anchor state 
[13] ensured that the anchor state was considered worse than 
the health states but better than death.
As a warm-up task, a set of practice profiles was chosen 
from the EQ-5D-3L profiles to allow participants to become 
familiar with the TTO task prior to valuing the study health 
states. Using practice profiles is a standard practice for TTO 
studies [14, 15] to improve participants’ understanding of 
the TTO exercise and thus improve data quality. Further, in 
our study, we also asked each participant to value an addi-
tional set of three different EQ-5D-3L profiles after evaluat-
ing the study-specific health states. The purpose of evaluat-
ing these extra profiles was to provide further comparisons 
between utility values derived from the conventional and 
chained TTO methods as those additional EQ-5D-3L pro-
files (11211, 12222, 23321) have directly elicited tariffs val-
ues from the UK population [15].
An A3-sized decision board was constructed to assist 
in the TTO interviews, and all of the health profiles were 
printed on coloured and laminated A6-size cards, using a 
different colour for each profile. The TTO materials and 
process were extensively tested and piloted as described 
elsewhere [13].
2.3  TTO Interviews
All interviews were conducted face to face by an interviewer 
trained in TTO methods (JS, MB and the other health econo-
mists listed in the acknowledgements). Interviews were most 
frequently conducted in participants’ own homes, and writ-
ten consent was taken prior to commencing the interview. 
Following the practice task, participants were asked to rank 
the six health state profiles from best to worst, after which 
the profile cards were shuffled by the interviewer and then 
evaluated by the participants in the TTO exercise. Follow-
ing valuation of the six profiles, participants were asked to 
value the three additional EQ-5D profiles, after which those 
in the chained group were given a practice task followed by 
valuation of the anchor state using the conventional TTO 
method (i.e. everyone valued 12 profiles in total, with those 
in the chained group being given a further two profiles). 
The iteration procedure resembled a ‘ping-pong’ approach 
[16], i.e. the length of the state being valued was alternated 
between 14 days and 1 day, 13 days and 2 days, etc. until the 
participant identified a time period where they were indiffer-
ent to the two states. While the board displayed only whole 
numbers of days, participants were informed that they could 
select a proportion of a day if they wished given the short 
timeframe.
2.4  Data Analysis
Information on the sociodemographic characteristics of the 
participants was collected and used in the analysis, including 
age, marital status, income, education, employment status, 
physical activity level and urban/rural residency. The latter 
two variables were included because it was assumed that 
participants’ usual physical activity level and the location 
of their residence would have an impact on how they valued 
those health states that would impact on their mobility.
Utility values were calculated as follows:
Conventional TTO: the Utility value for each health state 
(hi) was calculated using the formula hi = x/t, where x is the 
time point at which a participant is indifferent to spending 
x days in perfect health and t days in the health state (fixed 
at 14 days).
Chained TTO: The utility values for each health state (hi) 
and the anchor state (hj) were calculated using the follow-
ing formulas. In the first formula, x1 is the time point at 
which the participant is indifferent to spending x1 days in the 
anchor state and t days (14) in the health state. The second 
formula calculates the utility value for the anchor state (hj) 
using the conventional method where x2 is the time point at 
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which the participant is indifferent to being in the anchor 
state or t days (14) in perfect health:
The combined formula for calculating the utility value for 
each health state is then:
Tobit regressions of the elicited TTO values were per-
formed to derive predicted utility values for each health state 
controlling for sociodemographic characteristics. An addi-
tional control variable was created based on the consistency 
between the utility values derived and how each participant 
ranked those profiles prior to the TTO exercise to indicate 
data quality. Estimates of predicted utility values for each 
procedure and each elicitation method were then compared 
using t tests. Stata (version 14; StataCorp LP) was used to 
analyse the data. The regression equation is described as fol-
lows, where U is the elicited utility value, xi represents the 
set of explanatory variables, with α and ɛ as the constant and 
error term, respectively. This is performed for each of the 
six health profiles evaluated and the three additional EQ-5D 
profiles:
Separate models were performed for each health profile 
instead of being combined in a panel framework for two 
reasons. Firstly, the health state profiles were designed and 
valued as a whole for the needs of this study rather than 
selected based on systematic variations in the dimensions; 
therefore, dummy variables for the dimensions were not 
available to be included in the regressions, without which 
the health states utility values cannot be estimated in a panel 
framework. Secondly, running separate models allowed for 
the possibility that the impact of one or more of the control 
variables may not be uniform across the range of mild, mod-
erate and severe health states. This is especially important 
given the small sample size. Detailed regression results are 
presented in Appendix 4 (see the ESM).
3  Results
A total of 40 participants were recruited to the study, with 20 
allocated randomly to each TTO method. Two participants 
from the chained TTO group were excluded from the analy-
sis due to missing data (did not wish to value the anchor 
state) and non-trading (did not want to trade the anchor state 
hi = 1 −
(
1 − hj
)x1
t
hj =
x2
t
,
hi = 1 −
(
1 −
X2
t
)
X1
t
.
U = 훼 + 훽ixi + 휀.
with death), respectively. Of those included in the analysis, 
the average age was 54 years. The majority of the partici-
pants were married (84%), 34% had degree level and above 
education, 39% had a household income above £36,400, 
55% were employed and 29% were retired. Most of the par-
ticipants (71%) lived in the urban area. Levels of physical 
activity were reported at 29, 47 and 24% for high, median 
and low, respectively. Full summary statistics are given in 
Appendix 3 (see the ESM).
Overall, the mean estimated utility values consistently 
decreased with increasing severity of health states within 
each procedure for both TTO methods, demonstrating face 
validity of the elicited values.
Table 1 compares each of the predicted health state util-
ity values between the two procedures. For both types of 
TTO methods, utilities were lower for urethroplasty, but the 
difference was only significant for the severe health states 
as shown by the t statistics and their associated P values 
at a significance of above 95%. For all the other health 
states, there is no evidence of a difference between the two 
procedures.
Table 2 compares each of the predicted health state util-
ity values between the two TTO methods. For the mild 
and moderate health states, conventional TTO appeared to 
generate lower utility values than chained TTO, whereas 
for the severe health states the opposite is true. However, t 
test results suggest that the differences are not statistically 
significant except for the severe urethrotomy health state, 
where the t statistic is large enough to have a P value at 90%. 
However, this difference may still be due to chance given the 
small sample size, as the confidence intervals for the mean 
differences included 0.
Table 3 compares the predicted utility values for the addi-
tional EQ-5D-3L profiles evaluated at the end of the TTO 
exercise between the two TTO methods. Similar trends were 
observed where conventional and chained TTO methods 
appeared to generate similar utility values for mild and mod-
erate health states, but for the most severe health state, con-
ventional TTO resulted in a lower utility value than chained 
TTO, and the difference is statistically significant at 95%. 
Additionally, comparison with the EQ-5D-3L UK reference 
tariffs showed that for the mild profile (11211), there was 
no evidence of a difference between the predicted utility 
values from the conventional method and the national tariff. 
There were notable differences between all other predicted 
utility values and the national tariff, and the utility values 
generated in the present study are significantly higher than 
the national tariff.
The results appear to suggest that for mild or moderate 
health states, the utility values generated from both TTO 
methods appear to be robust, but the utility values are 
highly influenced by the TTO method chosen when more 
severe health states are considered.
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4  Discussion
Our review of the published literature suggests this is the 
first study to use TTO to capture short-term utilities asso-
ciated with interventions investigated in a clinical trial 
and one of a small number to use the chained TTO method 
[17]. Given the short-term nature of the health states being 
evaluated where conventional TTO was suggested to be 
subject to bias, this study also aimed to explore the per-
formances of two TTO methods in eliciting short-term 
utilities. However, as this was conceived as an exploratory 
first attempt, there was no intention to provide definitive 
estimates on the short-term utilities; hence, a small sam-
ple size was used to fit within the scope of the clinical 
study. Nevertheless, this study provides evidence of the 
Table 1  Comparing utility values between the surgical procedures
CI confidence interval, SD standard deviation, TTO time trade-off
***P < 0.01, **P < 0.05
Types of TTO methods Health states severity Urethrotomy, 
mean (SD)
Urethroplasty, 
mean (SD)
Mean difference 95% CI of mean 
difference
P value (t statistics)
Conventional (n = 20) Mild 0.81 (0.19) 0.79 (0.17) 0.01 − 0.04 to 0.07 0.59 (0.51)
Moderate 0.58 (0.30) 0.54 (0.24) 0.04 − 0.07 to 0.15 0.47 (0.72)
Severe 0.56 (0.24) 0.39 (0.27) 0.17*** 0.08 to 0.27 0.00 (3.81)
Chained (n = 18) Mild 0.83 (0.18) 0.83 (0.20) 0.01 − 0.03 to 0.04 0.77 (0.38)
Moderate 0.67 (0.21) 0.62 (0.15) 0.05 − 0.08 to 0.18 0.43 (0.81)
Severe 0.44 (0.19) 0.29 (0.20) 0.15** 0.02 to 0.28 0.04 (2.36)
Table 2  Comparing utility values between the TTO methods
CI confidence interval, SD standard deviation, TTO time trade-off
*P < 0.1
Surgical procedures Health states severity Conventional TTO, 
mean (SD) (n = 20)
Chained TTO, 
mean (SD) 
(n = 18)
Mean difference 95% CI of 
mean differ-
ence
P value (t statistics)
Urethrotomy Mild 0.81 (0.19) 0.83 (0.18) − 0.03 − 0.15 to 0.10 0.65 (− 0.44)
Moderate 0.58 (0.30) 0.67 (0.21) − 0.09 − 0.26 to 0.08 0.28 (− 1.04)
Severe 0.56 (0.24) 0.44 (0.19) 0.12* − 0.02 to 0.26 0.09 (1.73)
Urethroplasty Mild 0.79 (0.17) 0.83 (0.20) − 0.03 − 0.15 to 0.09 0.52 (−0.57)
Moderate 0.54 (0.24) 0.62 (0.15) − 0.08 − 0.21 to 0.05 0.23 (− 1.22)
Severe 0.39 (0.27) 0.29 (0.20) 0.10 − 0.06 to 0.25 0.22 (1.27)
Table 3  Comparing utility values elicited based on EQ-5D-3L profiles
CI confidence interval, SD standard deviation, TTO time trade-off
***P < 0.01, **P < 0.05
Health states 
(national tariff)
Conventional 
TTO, mean 
(SD) (n = 20)
Chained TTO, 
mean (SD) 
(n = 18)
Mean differ-
ence
95% CI of mean 
difference
P value (com-
parison between 
TTO methods) 
(t statistics)
P value (con-
ventional TTO 
compared to 
national tariff) 
(t statistics)
P value (chained 
TTO compared 
to national tariff) 
(t statistics)
EQ-5D profile 
11211 (0.869)
0.89 (0.11) 0.93 (0.09) − 0.04 − 0.11 to 0.02 0.18 (− 1.38) 0.41 (0.84) 0.01*** (3.20)
EQ-5D profile 
12222 (0.551)
0.79 (0.17) 0.78 (0.17) 0.01 − 0.10 to 0.12 0.83 (0.21) 0.00*** (6.34) 0.00*** (5.61)
EQ-5D profile 
23321 (0.147)
0.59 (0.24) 0.77 (0.17) − 0.17** − 0.31 to −0.03 0.02** (− 2.54) 0.00*** (8.29) 0.00*** (15.21)
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acceptability and feasibility of a TTO study conducted 
alongside a clinical trial, as well as some suggestions 
regarding justifications for using each TTO method.
While TTO studies often focus on health states over a 
period of several years [18, 19] or even ‘the rest of life’ 
[20], this study attempted to elicit utilities over a very 
short time period immediately following the treatment pro-
cedures. The estimated utility values associated with each 
procedure decrease as the health states become worse, sug-
gesting these estimations had face validity. The high rate 
of useable data indicates that conducting a TTO exercise 
alongside a clinical trial is both acceptable and feasible.
Comparison between the two procedures showed that 
although most differences were not statistically significant, 
lower utility values were associated with the urethroplasty-
related health states, which was expected as urethroplasty 
was the more invasive procedure. This finding suggests a 
greater decrement in HRQoL would be expected imme-
diately following the urethroplasty procedure. This could 
be because participants were particularly averse to one 
or more of the symptoms described in the urethroplasty 
health states. However, we cannot rule out a possible 
type 1 error due to the small sample size. Additionally, 
there is evidence suggesting TTO methods suffer from 
inherent bias, but findings have been mixed, with one study 
suggesting biases were associated with both the chained 
and conventional TTO methods [10], while another [21] 
showed that the chained method avoids biases observed 
using the conventional TTO.
Comparing the two TTO methods, there is no evidence 
that the estimated utility values differ for mild and mod-
erate health state profiles, but values did diverge when 
severe health states were considered. This pattern was 
observed for both the disease-specific health states and 
the additional EQ-5D-3L health states valued at the end of 
the interview, although the chained TTO produced lower 
utility for the worst disease-specific health state but higher 
utility for the worst EQ-5D-3L health state, which is an 
interesting and unexpected finding that requires further 
investigation with a sufficient sample size. Given the small 
sample size in our study, we cannot rule out this finding is 
simply due to chance.
A further unexpected finding to note is that utilities for 
12222 and 23321 EQ-5D-3L health states estimated in the 
present study were significantly higher than the national tar-
iff. While given the small sample size we do not want to be 
overly reliant on the statistical significance, we may specu-
late on reasons for this interesting finding: these EQ-5D-3L 
profiles were evaluated at the end of the TTO interview, and 
following the valuation of some very severe health states, 
participants may find those EQ-5D-3L profiles less severe in 
comparison; another possible explanation is that those EQ-
5D-3L profiles were valued by a patient population who had 
experienced some very distressing and troublesome health 
conditions, and therefore, they may consider the EQ-5D-3L 
profiles less severe than the general population whom the 
national tariff was based on. This may raise the question 
on the role a patient’s own medical history plays in their 
valuation of health states, which has been explored previ-
ously. For example, Jansen et al. [9] examined the stability of 
preferences before, during and after treatment. We were not 
able to examine the patient valuations against their treatment 
timeframe in the study, and future study design should aim 
to enable this for such investigation.
This study has a number of limitations. The most notable 
one is the small sample size, which means a wider standard 
deviation for all the study estimates, and we cannot rule 
out any finding being simply due to chance. The use of ran-
domisation to determine which TTO method a respondent 
received theoretically helped ensure the two groups were 
balanced and comparable. In practice, however, the small 
sample size means this may not be enough to ensure a bal-
anced sample between the two groups. Additionally, het-
eroscedasticity among study participants is inevitable with 
a small sample. To remedy those, we adjusted for observ-
able individual characteristics to estimate the utility values, 
which would help reduce potential bias in estimations; how-
ever, the regressions’ degree of freedom was sacrificed as 
a result of the added number of explanatory variables and 
small sample size, and this reduces the precision of the esti-
mates. Due to the limited scope of the present study, we were 
unable to test the external validity of the utility estimates, 
and given the small sample size, the study sample may not 
be representative of the patient population.
We have only been able to examine statistical significance 
when comparing the estimated results. A more meaningful 
investigation would be to examine whether these differences 
were relevant from a clinical perspective by considering 
estimated difference against the minimally important dif-
ference (MID) [22] for a TTO approach for the health states 
in question. For utility values associated with EQ-5D-3L 
(which was derived from responses to a set of conventional 
TTO questions), the MIDs have been variously estimated: a 
study examining MIDs from patients with a range of health 
conditions found a mean MID of 0.074 [23], and another 
study examining MIDs for cancer patients reported a mean 
MID of 0.09 [24]. Only the moderate and severe health 
states when comparing between TTO methods and severe 
health states when comparing between treatments in our 
study appear to exceed the MIDs found in the literature. 
This may indicate that a meaningful difference in HRQoL 
is only important when the health states are more distressing 
or troublesome. Correspondingly, for mild health states, the 
choice of TTO method may not be crucial because the dif-
ferences are not important to patients or clinicians. However, 
for more severe health states, we need to carefully consider 
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which TTO method to use. The issue of what the MID would 
be in this context is clearly important to explore, with the 
input from both patients and clinicians. Recent guidance has 
suggested alternative methods to do this [25, 26]. Further 
work could also be designed to evaluate clinicians’ as well 
as patients’ preferences over the health states in question, to 
better understand how the perceived impact from treatments 
may vary between patients and clinicians and aid shared 
decision making for patient-centred care [18].
Understanding of the short-term impact of the procedures 
would offer valuable information from a policy-making per-
spective as well as improve patient information on treat-
ment choices. Further work combining the TTO data with 
other observations such as relative incidence of side effects 
and recurrence rates may help to support decision making 
in the NHS regarding the choice between urethrotomy and 
urethroplasty.
The chained TTO may have a stronger theoretical base 
[11], and other studies using chained TTOs have suggested 
that this is a responsive method for eliciting preferences 
[9, 27, 28]. However, if the value of using chained TTO is 
not reflected in improving the accuracy of estimated utility 
values, it might not justify the additional burden and com-
plexity of replacing the conventional TTO in the instances 
of short-term health states valuation. Conventional TTO, 
on the other hand, is easier to design, administer and com-
plete. However, further research with a larger sample size is 
needed to establish the justification in the selection between 
the two TTO methods. There is also a need to investigate 
consistency and reliability within the same participant [10].
5  Conclusion
Using TTO to elicit utilities for short-term health states 
alongside a clinical trial has proven to be feasible and 
acceptable. While the study finding is preliminary, it 
suggests that undergoing urethroplasty or urethrotomy 
is likely to result in a decrement to HRQoL immediately 
post-operation, with the former resulting in likely higher 
utility losses. The tendency of men with urethral stric-
ture to require repeated treatments increases the clinical 
significance of this decrement, which should be incorpo-
rated into the QALY-based cost-effectiveness assessment 
of each treatment strategy in the longer term. This study 
also explored the rationale for applying the more complex 
chained TTO method for short-term health state valua-
tions. The indicative results suggest that chained TTO 
overall does not result in significantly different estimates 
from conventional TTO when the health states are mild 
or moderate. In the context of severe health states, there 
may be justification for the use of chained TTO. Fur-
ther research with a sample size calculation and direct 
comparison with an alternative method of deriving utili-
ties is needed to establish justification for the use of the 
chained TTO method if results are proven to be more 
accurate and robust. Future studies may also explore the 
potential to incorporate the TTO estimates in the cost-
effective analysis, with consideration given to achieving 
sufficient sample size and the selection of the TTO par-
ticipants (public, patients or clinicians) for the perspective 
of evaluation.
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